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Abstract Pseudomonas aeruginosa is an opportunistic bacterial
pathogen of great medical relevance. One of its major toxins,
exoenzyme S (ExoS), is a dual function protein with a
C-terminal Ras-ADP-ribosylation domain and an N-terminal
GTPase activating protein (GAP) domain specific for Rho-
family proteins. We report here the three-dimensional structure
of the N-terminal domain of ExoS determined by X-ray
crystallography to 2.4 Aî resolution. Its fold is all helical with a
four helix bundle core capped by additional irregular helices.
Loops that are known to interact with Rho-family proteins show
very large mobility. Considering the importance of ExoS in
Pseudomonas pathogenicity, this structure could be of interest
for drug targeting. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Pseudomonas aeruginosa is a major opportunistic human
pathogen. In part due to its natural resistance against anti-
biotics and disinfectants, it is a signi¢cant source of bacterial
infections in hospitalised patients, like for example severe
burn victims. Furthermore, long term colonisation of the
lungs by P. aeruginosa is the leading cause of mortality of
cystic ¢brosis patients [1].
Exoenzyme S (ExoS) is essential for virulence as the disrup-
tion of its gene drastically decreases the lethality of P. aeru-
ginosa [2]. It is secreted into host cells by a type III secretion
mechanism. Whereas the C-terminal domain of ExoS (resi-
dues 234^453) shows Ras-ADP-ribosylation activity [3], a
Rho-speci¢c GTPase activating protein (GAP) activity has
been localised in its N-terminal domain (residues 1^234) [4].
The Rho family proteins Rho, Rac and Cdc42 are GTP bind-
ing proteins acting like molecular switches that are involved in
the regulation of actin cytoskeleton rearrangements in a large
array of signaling processes [5]. Because Rho-family GTP
binding proteins also regulate macrophage-mediated phagocy-
tosis, it is thought that the N-terminal Rho-family-GAP ac-
tivity of ExoS is essential for protection of P. aeruginosa from
attack by the host immune system [4]. A similar function of
macrophage phagocytosis protection has been reported for
the ExoS-GAP homologue YopE of Yersinia sp. [6,7]. Where-
as ExoS in Pseudomonas and YopE in Yersinia are thus
thought to be part of a protective mechanism of bacteria
against host phagocytic cells, the ExoS homologue SptP in
Salmonella seems to have a somewhat di¡erent function. In
this organism, the GAP activity of SptP is part of an intricate
mechanism responsible for transforming non-phagocytic cells
temporarily so that they can internalise the bacterium. GAP
activity of SptP would in this model restore normal cytoskel-
eton function after injection of the guanine-nucleotide ex-
change factor (GEF) SopE induces endocytosis of the bacteria
through Rho-family-mediated cytoskeletal rearrangements
[8,9].
We have recently solved the crystal structure of the complex
between the ExoS GAP domain (termed ExoS-N from now
on) and human Rac1 [10]. Because of the potential impor-
tance of ExoS-N as a drug target, because the actual target
of drugs would be ExoS-N alone rather than the complex, and
in order to better understand structural determinants of the
domain during the enzymatic reaction, we have also solved
the structure of uncomplexed ExoS-N.
2. Materials and methods
Selenomethionine-substituted ExoS (96^234) was expressed as a re-
combinant GST fusion protein with the additional N-terminal amino
acids Gly^Ser^Ala (after thrombin cleavage) and a C-terminal haem-
agglutinin-tag using the Met auxotroph Escherichia coli strain B834
grown on minimal medium supplemented with SeMet. After a⁄nity
puri¢cation of the protein and concentration to 20 mg/ml in 25 mM
Tris-bu¡er pH 7.5, ExoS-N crystals were grown and improved by
microseeding at 20‡C in a solution containing 16% PEG 6000, 0.2 M
(NH4)2SO4, 10 mM MgCl2 and 100 mM Na^cacodylate pH 5.5 using
the hanging drop method. They were frozen in liquid N2 using pre-
cipitant solution supplemented to 30% PEG 6000, 2% isopropanol
and 4% ethylene glycol. Two di¡erent crystal forms were obtained
under these conditions: triangular plates, which belonged to space
group P1 and did not di¡ract very well and a rectangular crystal,
which belonged to the orthorhombic space group C2221 and dif-
fracted to 2.1 Aî resolution. Unit cell dimensions of the orthorhombic
crystal were a = 42.9 Aî , b = 55.7 Aî and c = 107.5 Aî with one ExoS-N
molecule per asymmetric unit.
A 2.4 Aî in house data set of this crystal was collected using a
Nonius rotating Cu-anode (V0 = 1.54 Aî ) with a MAR imaging plate
detector (MAR345). Additionally, multiwavelength anomalous disper-
sion (MAD) data were collected at three wavelengths corresponding
to the peak (V1 = 0.9790 Aî ), in£ection point (V2 = 0.9789 Aî ) and a high
energy remote point above the Se absorption edge (V3 = 0.8856 Aî )
using the BM-14 beamline at ESRF, Grenoble, France.
Re£ections were integrated with DENZO and scaled with SCALE-
PACK [11]. Two of the three Se atoms of ExoS-N could be identi¢ed
using Patterson analysis. The third Se atom was localised in a region
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with high B-factors and its re¢nement lead to a low occupancy.
SHARP [12] was used to estimate experimental phases at 2.1 Aî , giving
¢nal ¢gures of merit of 0.65 and 0.71 for centric and acentric re£ec-
tions, respectively. After density modi¢cation using DM [13], the re-
sulting maps allowed identi¢cation of most of the ExoS-N chain.
Chain building and examination was carried out with X¢t [14]. The
obtained model was re¢ned using CNS [15] with the 2.4 Aî home-
collected data set, because it led to the lowest crystallographic
R-factor. Re¢nement against the MAD data sets resulted in higher
R-factors, which could be due to radiation damage of the crystal. For
best results, experimental phases were included in the re¢nement using
maximum likelihood with incorporated experimentally determined
phase probability in terms of the Hendrickson and Lattman coe⁄-
cients (MLHL target of CNS)[16]. The ¢nal model consists of amino
acids 102^234 of ExoS-N as well as the ¢rst residue of the haemag-
glutinin-tag and 65 water molecules. It was re¢ned to an overall crys-
tallographic R-factor of 25.7% and R-free of 26.7%. PROCHECK
[17] revealed no amino acids with unfavourable x,8 main chain
angles.
Coordinates and structure factors have been deposited in the pro-
tein data bank (pdb) under accession number 1he9.pdb.
3. Results and discussion
The structure of ExoS-N was solved by SeMet-MAD phas-
ing using the crystal belonging to the orthorhombic space
group C2221. Fig. 1 shows details of the experimental electron
density map, which allowed the identi¢cation and building of
most of the ExoS-N protein chain. Amino acids 135^143 and
186^189 re¢ned to very high B-factors and could not be iden-
ti¢ed with the same clarity as the amino acids shown in Fig. 1.
The ¢nal model includes residues 102^234 of ExoS and 65
water molecules and is characterised by a ¢nal R-factor of
25.7% (R-free = 26.7%). The ¢nal crystallographic R-factor
could not be improved by further re¢nement, perhaps due
to the relatively large £exibility of the protein as indicated
by the overall B-factor of 62.3 Aî 2 (Table 1).
ExoS-N consists of a single almost all-helical protein do-
main of about 130 amino acids. Its overall structure is shown
in Fig. 2. The core of the domain is formed by a four helix
bundle built up by parts of the kinked helix 1, helix 3, helix 4
and the long C-terminal helix 7. One side of this structure is
capped by three additional helices (H2, H5 and H6), as well as
a very small two stranded L-sheet (S1, S2). Between the sec-
ond and the third helix, as well as between the ¢fth and the
sixth helix, two prominent loops protrude sideways. These
two bulges contain the most conserved sequences in the
GAP domain of ExoS and the related toxins ExoT, SptP of
Salmonella typhimurium and YopE of Yersinia sp. As shown
in our previous structure, they are important Rac binding
regions, bulge I being involved in the stabilisation of the cat-
alytic Gln61 of Rac and bulge II stabilising the catalytic Arg
146 of ExoS and making direct interactions with the oxygens
of the ribose of GDP [10].
Compared with our previously reported structure of the
ExoS-N^Rac complex[10], the ¢rst six amino acids of helix
1 (residues 96^101) of ExoS-N can not be identi¢ed in the
electron density maps. This indicates that in the complex
they are probably stabilised by the interaction of this helix
with Rac. Again compared to the complex, ¢ve additional
C-terminal amino acids could be seen in the electron density
maps, indicating that helix 7 is in fact larger than observed in
the complex structure. The ExoS-N structure therefore con-
¢rms by MAD phasing the unique ExoS-N fold that we have
recently determined in the context of the ExoS-N^human
Rac1 complex structure (Fig. 3). The overall root mean square
(r.m.s.) deviation for corresponding CK atoms of complexed
and unbound ExoS-N is 0.83 Aî . The highest deviation be-
tween both models is localised on the regions surrounding
the two important bulges (r.m.s. deviations of about 1.2 Aî ),
whereas the four helix bundle region shows very small devia-
Table 1
X-ray data collection and re¢nement statistics
V0 V1 V2 V3
Data collection
Wavelength (Aî ) 1.54 0.9789 0.9790 0.8856
Resolution range (Aî )a 20^2.4 (2.49^2.4) 30^2.1 (2.15^2.1) 30^2.1 (2.18^2.1) 30^2.1 (2.18^2.1)
Number of re£ections 68947 143634 116369 112509
Number of unique re£ections 5272 14016 13791 13429
Completeness (%)a 95.3 (98.4) 98.1 (90.4) 96.5 (82.2) 94 (88.6)
I/ca 34 (8) 24.3 (2.9) 27.1 (2.6) 23 (3.2)
R-sym (%)a 5.3 (17.5) 3.4 (25.8) 3.2 (30) 3.6 (28.9)
Phasing Power (Ano/Iso) ^ 3.5/8.3 2.8/6.8 2.5/^
Re¢nement
Resolution range (Aî ) 20^2.4
Re£ections 5237
Atoms 1067
R-cryst (%) 25.7
R-free (%)b 26.7
Average B-factor:
Protein (Aî 2) 62.4
Solvent (Aî 2) 61.6
r.m.s.d. from ideal values:
Bond lengths (Aî ) 0.016
Bond angles (‡) 2.06
Ramachandran plotc :
Residues in most favoured regions 89.7
Residues in additionally allowed regions 10.3
aValues in parentheses correspond to highest resolution shell.
bThe R-free factor was calculated with 10% of the data omitted from structure re¢nement.
cData calculated using the program PROCHECK [17].
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tions (r.m.s. deviations of 0.6 Aî ). Interestingly and contrary to
the situation in the ExoS-N^Rac complex, the bulge regions
have the highest B-factors of the structure, as indicated in Fig.
4. This ¢nding suggests that they are ordered during substrate
binding, thus following an induced ¢t mechanism.
The functional importance of £exible regions in substrate
binding has been described for a series of proteins and espe-
cially enzymes [18]. In the case of ExoS, one important role of
the £exibility of the bulge regions could be to allow for an
adjustment of the ExoS structure to di¡erent host cell target
proteins like Rho, Rac and Cdc42. Section 2 data [4] as well
as our previous structure [10] indeed support the conclusion
that ExoS binds with similar a⁄nity to all three GTPases. We
can however not entirely rule out that the conformational
changes and the increased mobility of the bulge regions ob-
served in the structure of uncomplexed ExoS are at least
partly in£uenced by crystal packing and the absence of trun-
cated parts of the molecule. In the case of the ¢rst region with
high B-factors (bulge I) there are no prominent crystal con-
tacts that could in£uence its conformation. In the case of
bulge II however, at least part of the observed r.m.s. deviation
could be explained by crystallographic clashes that would re-
sult if the chain had the same conformation as in the complex
structure.
The position of the side-chain of the catalytic arginine
Arg146 of ExoS-N can be located in both the experimental
electron density and omit maps of the ¢nal model. This den-
sity indicates that Arg146 occupies a slightly di¡erent confor-
mation in the uncomplexed protein structure as compared to
the complex structure. In this conformation, the arginine is
not stabilised by the bulge II residues Gly185 and Thr186 as it
is in the complex structure. This could indicate that the in-
Fig. 2. The ExoS-N fold. Helices that form the four helix bundle
core motif (H1bc, H3, H4, H7) are drawn in darker red, other heli-
ces (H1a, H2, H5, H6) in orange. Bulge I and Bulge II are high-
lighted in red and green, respectively. The catalytic arginine
(Arg146) is drawn as a ball-and-stick model. This ¢gure was drawn
with Molscript [32].
Fig. 3. Superposition of CK traces of ExoS-N structures. The CK
trace of the structure of uncomplexed ExoS-N (red) is superimposed
on to the ExoS-N structure from the ExoS-N^Rac1 complex (blue)
[10].
Fig. 1. Stereo view of the experimental electron density map of the four helix bundle region of ExoS-N contoured at 1 c. Upper part shows
the C-terminal helix H7 with Glu216, which forms a salt bridge to Arg174 of helix H4 (lower part). This ¢gure was produced with X¢t [14].
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creased motility of the bulges surrounding the catalytic argi-
nine has the function of increasing the degrees of freedom of
the catalytic arginine for better GTPase interaction.
The structure of isolated or GTPase-bound eukaryotic
GAPs for Ras [19^21], Rho [22^24], Rab [25], Ran [26] and
Arf [27] proteins have been solved. Ran GAPs and Arf GAPs
have an K,L-fold, the others are all-helical proteins. A com-
mon ancestry has been proposed for Ras and RhoGAPs
based on structural similarities [28^31]. As outlined in our
earlier report, ExoS-N has no structural homology to any of
these proteins. It has probably acquired an enzymatic mech-
anism very similar to eukaryotic GAPs by convergent evolu-
tion. An important feature that outlines this, is the di¡erent
arrangement of the four helix bundles towards the GTPase,
the di¡erent contacting amino acids, as well as the presence of
the catalytic arginine on a helix rather than a surface loop. In
contrast to ExoS, no dramatic changes in the mobility (B-
factors) of interacting residues can be detected if the com-
plexed and unbound structures of RasGAP [19,20] or Rho-
GAP [22,23] are compared. The structure of the unbound
GAP-related domain from neuro¢bromin, however, could
represent a situation similar to ExoS, since it has a similarly
high overall B-factor and elevated B-factors in the GTPase
contacting ¢nger-loop [21].
To conclude, the structure reported here con¢rms the
uniqueness of the ExoS-N fold as compared to eukaryotic
GAPs by an independent phasing method. The structure of
the ExoS-N monomer resembles globally the structure of
ExoS-N in complex with Rac, shows however increased mo-
bility and conformational changes of the important bulge I
and bulge II Rac1 interacting regions.
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Fig. 4. B-factor plot of ExoS-N. Average B-factors (in Aî 2) along
ExoS-N chain were calculated and plotted using the program bplot
[13]. The two regions with high B-factors correspond to the bulge I
and bulge II regions, respectively. Upper curve: uncomplexed ExoS-
N, lower curve: ExoS-N^Rac complex. Secondary structure is plot-
ted beneath the graph. B1, bulge I; B2, bulge II.
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